Invigor Group

Invigor Group to roll out its price tracking platform globally

Markets such as the U.S. and UK have higher competitor price tracking demand.

New client agreements to be finalised in the next few months

Invigor Group (ASX:IVO) is rolling out its cloud-based SpotLite competitor price tracking platform across the U.S., Europe and other markets following its successful Australian rollout earlier this year.

The international launch will allow Invigor to capitalise on the fast growth of big data, dynamic pricing and data analytics for various industries and markets around the world.

Building on the successful full-scale launch in Australia with already over 75% take up rate, SpotLite has clients such as Treasury Wines in multiple overseas markets.

Invigor is strengthening its international presence by fully launching in the U.S., Asia, UK, Western Europe, South America and the Middle East.

Markets such as the U.S. and UK have higher competitor price tracking demand than Australia, which is driven by market juggernauts such as eBay and Amazon.

This makes SpotLite a suitable solution for retailers seeking to be more competitive whether they are traditional online retailers, eBay and Amazon stores or individual sellers.

Invigor currently tracks more than 95,000 products across 40 industry verticals, gathering market intelligence data from over 950,000 product page URLs across hundreds of websites.

The company has secured local partnerships with eBay and GoDaddy, which will also be leveraged internationally.

Other partnerships are in the pipeline to be finalised within the next few months, which is expected to further drive reach and conversions.

Quick facts: Invigor Group

Price: $0.00

Market: ASX
Market Cap: $7.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian...

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer. The CEO said the first part of the study has shown some very...

3 hours, 1 minute ago

2 min read